Go Back This article was viewed 29 times

Case report


Renal Granulomatosis Post Intravesical Bacillus Calmette-Guerin Therapy for Non-muscle-invasive Bladder Cancer.

Karen Tran-HardingRashmi T NairHalemane Ganesh
Department of Diagnostic Radiology, University of Kentucky Chandler Medical Center, Lexington, KY, USA
Date of Submission: 05-Nov-2017, Date of Acceptance: 19-Feb-2018, Date of Web Publication: 18-Apr-2018.
Corresponding Author:
Corresponding Author

Karen Tran‑Harding

Department of Diagnostic Radiology, University of Kentucky Chandler Medical Center, 800 Rose Street, HX315E, Lexington, KY, USA.
E-mail: karentran@uky.edu

Corresponding Author:
Corresponding Author

Karen Tran‑Harding

Department of Diagnostic Radiology, University of Kentucky Chandler Medical Center, 800 Rose Street, HX315E, Lexington, KY, USA.
E-mail: karentran@uky.edu

DOI: 10.4103/jcis.JCIS_83_17 Facebook Twitter Google Linkedin

ABSTRACT


Intravesical Bacillus Calmette-Guerin (BCG) immunotherapy is a proven, effective treatment for intermediate- and high-risk non-muscle-invasive bladder cancer. Minor side effects are common and expected but systemic effects can occur in <5% of treated patients. We present a rare case of a 49-year-old male that presented with fever and chills after 3 weeks of intravesical BCG therapy post transurethral resection of bladder tumor. New renal lesions were present on contrast-enhanced computed tomography scan which was histologically proven to be necrotizing renal granulomatosis.
Keywords: Bacillus Calmette–Guerin, non-muscle-invasive bladder cancer, renal granulomas, urothelial carcinoma

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.